ImmuneOnco Launches Global Registrational Strategy for Anti-Tumor Drug with Instil

MT Newswires Live09-16

ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541), in partnership with US-based Instil, unveiled a global registrational strategy for anti-tumor drug IMM2510/SYN-2510 in combination with chemotherapy for front-line non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC), a Monday bourse filing said.

In China, ImmuneOnco is expediting the development of IMM2510/SYN-2510 in front-line NSCLC by targeting the start of a Phase 1b/2 front-line chemo combination study in late 2024. The company is also speeding up the development of IMM2510/SYN-2510 in front-line TNBC with initial Phase 1b/2 chemotherapy combination studies set to begin in early 2025.

In the US, Instil plans to submit an investigational new drug (IND) application for IMM2510/SYN-2510 for NSCLC and TNBC to the US Food & Drug Administration in late 2024, starting with a Phase 2 trial.

Shares of the company closed over 35% higher on Monday.

Price (HKD): $6.68, Change: $+1.7, Percent Change: +35.22%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2467172814?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-16 20:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2467172814","market":"nz","top_or_hot":-1,"title":"ImmuneOnco Launches Global Registrational Strategy for Anti-Tumor Drug with Instil","media":"MT Newswires Live","content":"<html><body><p> ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541), in partnership with US-based Instil, unveiled a global registrational strategy for anti-tumor drug IMM2510/SYN-2510 in combination with chemotherapy for front-line non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC), a Monday bourse filing said.</p><p>In China, ImmuneOnco is expediting the development of IMM2510/SYN-2510 in front-line NSCLC by targeting the start of a Phase 1b/2 front-line chemo combination study in late 2024. The company is also speeding up the development of IMM2510/SYN-2510 in front-line TNBC with initial Phase 1b/2 chemotherapy combination studies set to begin in early 2025.</p><p>In the US, Instil plans to submit an investigational new drug (IND) application for IMM2510/SYN-2510 for NSCLC and TNBC to the US Food &amp; Drug Administration in late 2024, starting with a Phase 2 trial.</p><p>Shares of the company closed over 35% higher on Monday.</p><p>Price (HKD): $6.68, Change: $+1.7, Percent Change: +35.22%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmuneOnco Launches Global Registrational Strategy for Anti-Tumor Drug with Instil</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmuneOnco Launches Global Registrational Strategy for Anti-Tumor Drug with Instil\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-16 20:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541), in partnership with US-based Instil, unveiled a global registrational strategy for anti-tumor drug IMM2510/SYN-2510 in combination with ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HKD","symbol_name":"尚乘数科","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2467172814","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2467172814","pubTimestamp":1726488530,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"ImmuneOnco Biopharmaceuticals  , in partnership with US-based Instil, unveiled a global registrational strategy for anti-tumor drug IMM2510/SYN-2510 in combination with chemotherapy for front-line non-small cell lung cancer  and triple-negative breast cancer , a Monday bourse filing said.In China, ImmuneOnco is expediting the development of IMM2510/SYN-2510 in front-line NSCLC by targeting the start of a Phase 1b/2 front-line chemo combination study in late 2024. The company is also speeding up the development of IMM2510/SYN-2510 in front-line TNBC with initial Phase 1b/2 chemotherapy combination studies set to begin in early 2025.In the US, Instil plans to submit an investigational new drug  application for IMM2510/SYN-2510 for NSCLC and TNBC to the US Food & Drug Administration in late 2024, starting with a Phase 2 trial.Shares of the company closed over 35% higher on Monday.Price : $6.68, Change: $+1.7, Percent Change: +35.22%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HKD":"尚乘数科","BK4526":"热门中概股","BK4588":"碎股","BK4023":"应用软件","BK7095":"多种金属与采矿","BK1161":"生物科技","IND.AU":"Industrial Minerals Ltd","BK4585":"ETF&股票定投概念","01541":"宜明昂科-B"},"translate_title":"ImmuneOnco与Instil启动抗肿瘤药物全球注册战略","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HKD":1,"IND.AU":1,"01541":0.9},"content_text":"ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541), in partnership with US-based Instil, unveiled a global registrational strategy for anti-tumor drug IMM2510/SYN-2510 in combination with chemotherapy for front-line non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC), a Monday bourse filing said.In China, ImmuneOnco is expediting the development of IMM2510/SYN-2510 in front-line NSCLC by targeting the start of a Phase 1b/2 front-line chemo combination study in late 2024. The company is also speeding up the development of IMM2510/SYN-2510 in front-line TNBC with initial Phase 1b/2 chemotherapy combination studies set to begin in early 2025.In the US, Instil plans to submit an investigational new drug (IND) application for IMM2510/SYN-2510 for NSCLC and TNBC to the US Food & Drug Administration in late 2024, starting with a Phase 2 trial.Shares of the company closed over 35% higher on Monday.Price (HKD): $6.68, Change: $+1.7, Percent Change: +35.22%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2467172814"}